Physician profile
William R Smith
NPI 1770842890
$5,798.56
in general payments reported to CMS, 2019-2025
44 companies · $1,512 in 2025
The $1,512 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $127 · 2021: $545 · 2022: $347 · 2023: $1,400 · 2024: $1,629 · 2025: $1,512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,541.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,540.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $941.22 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $833.64 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $599.06 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $548.38 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Corium, LLC | $300.72 | 2023-2025 | Azstarys |
| Amgen INC. | $297.68 | 2019-2025 | Repatha, Otezla, Evenity |
| Organogenesis INC. | $215.14 | 2019-2025 | Apligraf |
| Otsuka America Pharmaceutical, INC. | $206.67 | 2023-2025 | Rexulti, Abilify Maintena |
| Pfizer INC. | $197.39 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $142.89 | 2021-2024 | Verquvo, Gardasil 9, Belsomra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $127.94 | 2021-2025 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $108.24 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $102.85 | 2024-2025 | Caplyta |
| Lilly USA, LLC | $102.18 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.09 | 2021-2024 | Jardiance |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $91.41 | 2023-2024 | Yupelri |
| Janssen Pharmaceuticals, INC | $85.14 | 2021-2022 | |
| Viatris Specialty LLC | $77.75 | 2025 | Yupelri |
| Smith+Nephew, INC. | $77.21 | 2024 | Grafix Pl, Collagenase Santyl |
| Sumitomo Pharma America, INC. | $58.75 | 2023-2025 | Gemtesa |
| Abbott Laboratories | $52.67 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $41.06 | 2019 | |
| Astellas Pharma US INC | $40.29 | 2021-2023 | Veozah |
| Axsome Therapeutics, INC. | $36.55 | 2024-2025 | Auvelity |
| Exact Sciences Corporation | $34.29 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Allergan, INC. | $34.16 | 2019-2020 | |
| Pulmonx Corporation | $30.08 | 2023 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Eisai INC. | $26.66 | 2021 | |
| Vanda Pharmaceuticals INC. | $21.96 | 2025 | Fanapt |
| Sunovion Pharmaceuticals INC. | $21.29 | 2021 | |
| Seqirus USA INC | $21.20 | 2025 | Flucelvax, Fluad |
| Lundbeck LLC | $20.21 | 2024 | Vyepti |
| Inspire Medical Systems, INC. | $19.86 | 2025 | Inspire |
| E.R. Squibb & Sons, L.L.C. | $19.26 | 2024 | Eliquis |
| Lifescan, INC. | $18.83 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.68 | 2025 | Trintellix |
| Hologic Sales and Service, LLC | $18.11 | 2024 | Aptima |
| Ultragenyx Pharmaceutical INC. | $17.82 | 2020 | |
| Horizon Therapeutics Plc | $17.73 | 2020 | |
| Aimmune Therapeutics, INC. | $17.07 | 2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $15.59 | 2025 | Voquezna |
| Dexcom, INC. | $15.07 | 2021 | |
| Dynavax Technologies Corporation | $13.45 | 2023 | Heplisav-B |
| Organon LLC | $12.32 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.